Prognostic value of epidermal growth factor-receptor, T138 and T43 expression in bladder cancer.

por Ravery, V., Colombel, M., Popov, Z., Bastuji, S., Patard, J. J., Bellot, J., Abbou, C. C., Fradet, Y., Chopin, D. K.
Publicado 1995

Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling

por Xylinas, E, Cha, E K, Sun, M, Rink, M, Trinh, Q-D, Novara, G, Green, D A, Pycha, A, Fradet, Y, Daneshmand, S, Svatek, R S, Fritsche, H-M, Kassouf, W, Scherr, D S, Faison, T, Crivelli, J J, Tagawa, S T, Zerbib, M, Karakiewicz, P I, Shariat, S F
Publicado 2012

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

por Fradet, Y, Bellmunt, J, Vaughn, D J, Lee, J L, Fong, L, Vogelzang, N J, Climent, M A, Petrylak, D P, Choueiri, T K, Necchi, A, Gerritsen, W, Gurney, H, Quinn, D I, Culine, S, Sternberg, C N, Nam, K, Frenkl, T L, Perini, R F, de Wit, R, Bajorin, D F
Publicado 2019